| International Session（Symposium）5(JSGS・JSGE・JGES) |
| Fri. November 6th 9:30 - 12:00 Room 3: Kobe International Exhibition Hall No.2 Building Conference Room 3A |
| Pathological response and adjuvant chemotherapy were associated with recurrence after neoadjuvant chemotherapy for borderline resectable pancreatic cancer with arterial involvements | |||
| Kei Saito1, Yousuke Nakai1, Kazuhiko Koike1 | |||
| 1Department of Gastroenterology, The University of Tokyo | |||
|
|||
|
|||
| Background: Recently the efficacy of neoadjuvant chemo(radiation)therapy (NAC) was reported for borderline resectable pancreatic cancer (BR PC). We conducted a retrospective analysis of recurrence free survival (RFS) after NAC for BR PC with arterial involvement (BR-A PC). Methods: Consecutive patients with BR-A PC who underwent NAC at our hospital were retrospectively studied. Results: A total of 46 patients with BR-A PC received NAC (23 gemcitabine, S-1 and leucovorin and 23 nab-paclitaxel and gemcitabine) between January 2014 and July 2019. Median age was 71, male was 52%, performance status was 0 in 63.0% and median pretreatment CA19-9 was 264 U/ml. A median duration of NAC was 2.6 months. Surgical resection was performed in 76% and R0 resection rate was 61%. Pathological response was grade 2/3 in 31%. After surgical resection, adjuvant chemotherapy was administered in 66%. During the median follow-up of 15 months after surgical resection, 20 patients (63%) developed recurrence. The median RFS was 9.3 (95% CI, 5.6-16.5) months. The multivariate analysis revealed Grade 1 pathological response (p=0.03) and no adjuvant chemotherapy (p<0.01) as independent prognostic factors for RFS. Neither NAC regimen nor R1 resection were prognostic of RFS. Conclusion: In our cohort of BR-A PC undergoing NAC, pathological response and adjuvant chemotherapy were associated with longer RFS. |
|||
|
Index Term 1: pancreatic cancer Index Term 2: neoadjuvant chemotherapy |
|||
| Page Top | |||